PCFTF News Alert Pacific Therapeutics (PCFTF) 0.0265 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pacific Therapeutics (PCFTF) 0.0265 $PCFTF

Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbx995/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AdAlta - AnaptysBio - Auspex Pharmaceuticals - BiOrion Technologies - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgeneration - Chong Kun Dang Pharmaceutical - Compugen - Corridor Pharmaceuticals - F. Hoffmann-La Roche - FibroGen - GenKyoTex - Gilead Sciences - GlaxoSmithKline - HanAll Biopharma - Histocell - ImmuneWorks - IntelGenx - InterMune - Kasiak Research - LTT Bio-Pharma - Lanthio Pharma - MSM Protein Technologies - MedImmune - Moerae Matrix - Pacific Therapeutics - Pharmaxis Limited - ProMetic Life Sciences For more information visit http://www.researchandmarkets.com/research/pbx995/idiopathic
BIIB: 340.89 (+5.13), GILD: 91.29 (+1.84), CGEN: 8.58 (-0.17), ASPX: 49.93 (-0.10), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01)

Pacific Therapeutics Announces First Nine Months 2014 Financial Results
ACCESSWIRE - Tue Dec 02, 3:54PM CST
VANCOUVER, BC / ACCESSWIRE / December 2, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (1P3.F) (the "Company" has completed a phase 1 trial of its lead product for fibrosis, PTL-202, (a $4 billion market opportunity) with positive results and is advancing its sublingual formulation for erectile dysfunction (ED) to a pivotal bioequivalence trial.

CEO Comments on Diagnostic Breakthrough for Pulmonary Fibrosis
ACCESSWIRE - Thu Nov 13, 7:35AM CST
VANCOUVER, BC, Canada / ACCESSWIRE / November 13, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $4 billion plus market opportunities.

Pacific Therapeutics CEO Comments on Big Pharmas Recent Interest In Acquiring Therapies to treat Fibrosis
ACCESSWIRE - Thu Nov 06, 7:32AM CST
VANCOUVER, BC, Canada / ACCESSWIRE / November 6, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $4 billion plus market opportunities.

Pacific Therapeutics Ltd. Issues Stock Options to Consultants
TheNewswire.ca - Wed Nov 05, 9:05AM CST
(via Thenewswire.ca)

Pacific Therapeutics Shares Article Explaining Rose Mcgowan's Kiss IPF Goodbye Campaign
ACCESSWIRE - Thu Oct 09, 7:31AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / October 9, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

Pacific Therapeutics Annonuces Closing Of Non-Brokered Financing
ACCESSWIRE - Thu Oct 02, 7:40AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / October 2, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities.

Pacific Therapeutics Announces Amendment to Non-Brokered Financing
ACCESSWIRE - Tue Sep 23, 7:31AM CDT
VANCOUVER, BC / ACCESSWIRE / September 23, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

Pacific Therapeutics Shares Vancouver Sun Article Explaining Positive Impact of Cannabis on Child Having Epileptic Seizures and Need for New Formulations
ACCESSWIRE - Tue Sep 16, 7:06AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / September 16, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

Update on PTL-202, a Treatment for Progressive Organ Scarring, a $1.1 Billion Opportunity
ACCESSWIRE - Thu Sep 04, 7:39AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / September 4, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.
ITMN: 73.89 (-0.02)

Vantage Wire Publishes Report on Pacific Therapeutics Partner Vodis Innovative Pharmaceuticals
ACCESSWIRE - Tue Sep 02, 3:32PM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / September 2, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

Pacific Therapeutics Announces First Six Months 2014 Financial Results
ACCESSWIRE - Thu Aug 28, 5:13PM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / August 28, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTCBB: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on erectile dysfunction and diseases of excessive scarring (fibrosis) which are $1 billion plus market opportunities.

H.C. Wainwright Initiates Coverage of Pacific Therapeutics Partner Intelgenx with a Buy Recommendation
ACCESSWIRE - Fri Aug 15, 7:48AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / August 15, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

Vodis Pharmaceuticals and Pacific Therapeutics Agree to Share Technologies to Deliver Cannabinoid Based Therapies
ACCESSWIRE - Tue Aug 05, 8:08AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / August 5, 2014 / Vodis Pharmaceuticals (CSE: VP) (the "Company" The Company is pleased to announce that it has signed a term sheet with Pacific Therapeutics ("Pacific" agreeing to work with Pacific on the development of therapies based on extracts from cannabis plants, as previously announced by Pacific Therapeutics (PT:cse).

Pacific Therapeutics Annonuces Non-Brokered Financing
ACCESSWIRE - Tue Aug 05, 7:33AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / August 5, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

Proactive Investor Publishes Article on Pacific Therapeutics
ACCESSWIRE - Fri Jul 25, 7:32AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / July 25, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 139

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 161

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 158

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 71

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 129

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 111

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 104

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 125

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 142

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading

Top 5 Most Recently Viewed Articles

Unleashing Innovations: The Growth of Chronic Venous Insufficiency Treatments

Updated Category News Views 216

Chronic Venous Insufficiency Market Dynamics Chronic venous insufficiency (CVI) is a common public health concern that affects circulation in the lower limbs. Recent projections indicate a remarkable growth trend, expecting a compound annual growth rate (CAGR) of 9.4% from 2025 to 2034. This uptick stems from the advent of groundbreaking therapies and advanced medical...

Continue Reading
BSTR Miner Unveils Smart Contract Mining for All Investors

Updated Category News Views 343

BSTR Miner Introduces Innovative Smart Contract Mining Service BSTR Miner stands out as a premier cloud mining platform, now proudly offering its new smart contract mining service. This revolutionary service aims to streamline the often-complex world of traditional mining by integrating AI-driven dynamic profit optimization, automated contract generation, and elastic...

Continue Reading
UKG Expands Global Presence with New Operations Hub in Ireland

Updated Category News Views 256

UKG Expands Its Presence in Ireland UKG, a leading provider of HR, payroll, workforce management, and culture solutions, has unveiled plans for its new Global Operations Hub in Kilkenny, Ireland. This exciting initiative includes the creation of around 200 new jobs, primarily focusing on cybersecurity. This move reflects UKG's dedication to expanding its operations and...

Continue Reading
Cathie Wood's Bold Moves: Selling Off Block and Moderna Shares

Updated Category News Views 162

Cathie Wood's Strategic Moves with Ark Invest Cathie Wood, the founder and CEO of Ark Invest, is known for her bold investment strategies, especially concerning innovative companies. Recently, her firm made notable trades with Block Inc and Moderna, hinting at her current viewpoint in the fast-evolving investment landscape. Significant Trade with Block Inc In the last...

Continue Reading
Eurocastle Highlights Leadership Share Transactions and Vision

Updated Category News Views 132

Eurocastle Investment Limited Announces Key Share Transactions EUROCASTLE INVESTMENT LIMITED Contact: Oak Fund Services (Guernsey) Limited Company Administrator Attn: Nicole Barnes Tel: +44 1481 752957 Eurocastle announces Director/PDMR Dealing Notification In line with obligations under relevant regulations, Eurocastle Investment Limited has shared significant updates...

Continue Reading